What would be the difference between a Phase 2 and Phase 3 trial for HER-Vaxx?
If Phase 2 was going so well that it was unethical for it to continue, how would a Phase 3 trial be justified?
On one hand HER-Vaxx has proved efficacy (at least to IMU's IDMC) to the point that no sufferer should be denied it.
On the other, the sample size is still too small for Big Pharma to be interested or for IMU to seek FDA approval to commercialise.
Would be great if this Catch-22 was clarified ...
What would be the difference between a Phase 2 and Phase 3 trial...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.1¢ |
Change
-0.007(8.97%) |
Mkt cap ! $519.7M | |||
| Open | High | Low | Value | Volume |
| 7.8¢ | 8.0¢ | 7.0¢ | $4.930M | 66.98M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 571382 | 7.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 1102836 | 5 |
View Market Depth
| Last trade - 16.10pm 19/04/2024 (20 minute delay) ? |
|
|||||
|
Last
7.1¢ |
Change
-0.007 ( 10.7 %) |
||||
| Open | High | Low | Volume | ||
| 7.8¢ | 8.0¢ | 7.0¢ | 28787854 | ||
| Last updated 15.59pm 19/04/2024 ? | |||||
| IMU (ASX) Chart |